Details for New Drug Application (NDA): 070249
✉ Email this page to a colleague
NDA 070249 describes NITROFURANTOIN MACROCRYSTALLINE, which is a drug marketed by Watson Labs and is included in two NDAs. Additional details are available on the NITROFURANTOIN MACROCRYSTALLINE profile page.
The generic ingredient in NITROFURANTOIN MACROCRYSTALLINE is nitrofurantoin, macrocrystalline. Twenty-eight suppliers are listed for this compound. Additional details are available on the nitrofurantoin, macrocrystalline profile page.
The generic ingredient in NITROFURANTOIN MACROCRYSTALLINE is nitrofurantoin, macrocrystalline. Twenty-eight suppliers are listed for this compound. Additional details are available on the nitrofurantoin, macrocrystalline profile page.
Summary for 070249
| Tradename: | NITROFURANTOIN MACROCRYSTALLINE |
| Applicant: | Watson Labs |
| Ingredient: | nitrofurantoin, macrocrystalline |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 100MG | ||||
| Approval Date: | Jun 24, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
